Ney Carter Borges: Contemporary Trends and Outcomes of Percutaneous Coronary Intervention for Stent Thrombosis
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
”Contemporary Trends and Outcomes of Percutaneous Coronary Intervention for Stent Thrombosis
Stent thrombosis (ST) remains one of the most serious complications following percutaneous coronary intervention (PCI), frequently presenting as acute myocardial infarction (AMI). A contemporary analysis from the National Cardiovascular Data Registry (NCDR) CathPCI registry evaluated trends and outcomes of PCI performed for ST between April 2018 and June 2023. The study included 2,023,032 patients undergoing PCI for AMI, of whom 57,268 cases (2.8%) were attributed to stent thrombosis.
Regarding timing, very late ST (>365 days) represented the largest proportion of cases (49.5%), followed by early ST (≤30 days) at 31.8%, late ST (31–365 days) at 15.4%, and unknown timing in 3.4% of cases. Importantly, the incidence of PCI for ST remained stable over time, despite advances in contemporary PCI techniques, including newer-generation drug-eluting stents, potent P2Y12 inhibitors, and intracoronary imaging.
Clinically, patients with ST tended to be younger, more frequently male, and more likely to present with STEMI, cardiogenic shock, cardiac arrest, and ventricular arrhythmias, reflecting a high-risk population. Compared with PCI for non-ST lesions, PCI performed for ST was associated with significantly worse in-hospital outcomes, including higher rates of major adverse cardiac events (adjusted OR 1.24), all-cause mortality (OR 1.17), recurrent myocardial infarction (OR 1.80), and major bleeding (OR 1.18).
These findings highlight that, despite technological and pharmacologic advances, stent thrombosis remains a rare but high-risk complication of PCI, emphasizing the need for improved preventive strategies, optimized antithrombotic therapy, and procedural techniques to reduce its clinical impact.”
Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation